View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
July 29, 2022

Schizophrenia trials continue to test drug candidates as Covid-19 pandemic continues

A total of 127 planned schizophrenia clinical trials are planned to be held over the coming years.

By GlobalData Healthcare

Schizophrenia Awareness Day, marked on 25 July, is a national observance that aims to raise awareness about this mental illness. Schizophrenia is a chronic brain disorder that affects a person’s ability to function, such as thinking and feeling. According to GlobalData’s Epidemiology and Market Size database, epidemiologists estimate there are more than 21 million prevalent cases within the tracked 16 countries. Recent studies have also discovered that schizophrenia is the second biggest risk factor of mortality from Covid-19.

For the last five years (2017 to 2021), there has been a steady increase in the total number of schizophrenia clinical trials by trial start year, apart from 2020, a decrease that may be due to the focus on Covid-19 relief. Last year saw the most with 167 trials. This trend could indicate more research and development (R&D) expenditure on the disease.

A total of 127 planned schizophrenia trials are upcoming, with Cerevel Therapeutics and Newron Pharmaceuticals being the sponsors with the most planned schizophrenia clinical trials (five). The other top sponsors can be seen in Figure 1.

Cerevel Therapeutics, a US-based biopharmaceutical company, will continue trials using its primary schizophrenia drug candidate, emraclidine. The drug candidate acts by targeting muscarinic acetylcholine receptor M4 and is a positive allosteric modulator (PAM). It is administered through the oral route. Cerevel Therapeutics has two Phase II/III trials and three Phase III trials planned.

Newron Pharmaceuticals, an Italian biopharmaceutical company, will test evenamide, an orally administered drug candidate that acts by targeting voltage-gated sodium channels including Nav 1.3, 1.7, and 1.8. As with Cerevel Therapeutics, Newron Pharmaceuticals has two Phase II/III trials and three Phase III trials planned.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology